AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial
AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing...
Sanofi
Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter...
Sanofi’s Rilzabrutinib Meets Primary Endpoint in Phase III ITP Trial
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its Phase III trial for rilzabrutinib,...
Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...
Sanofi Explores Sale of Amunix Pharmaceuticals as It Shifts Focus to Immunology
Sanofi (NASDAQ: SNY), the France-based pharmaceutical giant, is reportedly in talks with potential buyers for...
Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation
France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics...
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...
Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort
Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...
Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools
Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...
Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food...
Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint
Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...
Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the...
Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...
Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients
The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...
Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced the acquisition of INBRX-101, a promising candidate...
Sanofi’s Dupixent Receives FDA Label Update for Atopic Dermatitis Patients with Hand or Foot Involvement
Sanofi (NASDAQ: SNY) has been granted authorization by the US Food and Drug Administration (FDA)...
Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies
Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...
AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA
AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...
Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...